NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Jakubowitz Law
announces that a securities fraud class action lawsuit has
commenced on behalf of shareholders of Reata Pharmaceuticals, Inc.
(NASDAQ: RETA).
To receive updates on the lawsuit, fill out the
form:
https://claimyourloss.com/securities/reata-pharmaceuticals-inc-loss-submission-form-2/?id=23798&from=4
This lawsuit is on behalf of persons and entities that purchased
or otherwise acquired Reata securities, and/or sold Reata put
options, between November 9, 2020 and
December 8, 2021, inclusive.
Shareholders interested in acting as a lead plaintiff
representing the class of wronged shareholders have until
February 18, 2022 to petition
the court. Your ability to share in any recovery doesn't require
that you serve as a lead plaintiff.
According to a filed complaint, Reata Pharmaceuticals, Inc.
issued materially false and/or misleading statements and/or failed
to disclose that: (1) the Food and Drug Administration had raised
concerns regarding the validity of the clinical study designed to
measure the efficacy and safety of bardoxolone for the treatment of
chronic kidney disease caused by Alport syndrome; (2) as a result,
there was a material risk that Reata's New Drug Application would
not be approved; and (3) as a result of the foregoing, defendants'
positive statements about the Company's business, operations, and
prospects were materially misleading and/or lacked a reasonable
basis.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities fraud. Attorney
advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/reta-shareholder-alert-jakubowitz-law-reminds-reata-shareholders-of-a-lead-plaintiff-deadline-of-february-18-2022-301485453.html
SOURCE Jakubowitz Law